Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
Alternative names
lenvatinib (lenvima) (1 trial)
liocyx (2 trials)
mrna hbv/tcr t-cells (1 trial)
tcr redirected t cells (1 trial)
tcr-t cells (1 trial)
Carcinoma (Phase 2)
Carcinoma, Hepatocellular (Phase 2)
Trials (5 total)
Trial APIs (5 total)